MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC ; volume:50 ; number:11 ; year:2020 ; pages:1810-1819 ; extent:10
European journal of immunology ; 50, Heft 11 (2020), 1810-1819 (gesamt 10)

Creator: Koh, Jiae
Kim, Youjin
Lee, Kyoung Young
Hur, Joon Young
Kim, Mi Soon
Kim, Boram
Cho, Hee Jin
Lee, Yeong Chan
Bae, Yeon Hee
Ku, Bo Mi
Sun, Jong‐Mu
Lee, Se‐Hoon
Ahn, Jin Seok
Park, Keunchil
Ahn, Myung‐Ju

DOI: 10.1002/eji.202048534

URN: urn:nbn:de:101:1-2022062407465909183395

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:37 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Koh, Jiae
Kim, Youjin
Lee, Kyoung Young
Hur, Joon Young
Kim, Mi Soon
Kim, Boram
Cho, Hee Jin
Lee, Yeong Chan
Bae, Yeon Hee
Ku, Bo Mi
Sun, Jong‐Mu
Lee, Se‐Hoon
Ahn, Jin Seok
Park, Keunchil
Ahn, Myung‐Ju

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

CD8+ T cell-based cancer immunotherapy

HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Impact of NSCLC metabolic remodeling on immunotherapy effectiveness

PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

Adoptive immunotherapy via CD4+ versus CD8+ T cells

Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients

Machine learning identifies prognostic subtypes of the tumor microenvironment of NSCLC

Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

CD8+ T cell-based cancer immunotherapy

HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Impact of NSCLC metabolic remodeling on immunotherapy effectiveness

PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

Adoptive immunotherapy via CD4+ versus CD8+ T cells

Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients

Machine learning identifies prognostic subtypes of the tumor microenvironment of NSCLC

Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

CD8+ T cell-based cancer immunotherapy

HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Impact of NSCLC metabolic remodeling on immunotherapy effectiveness

PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

Adoptive immunotherapy via CD4+ versus CD8+ T cells

Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients

Machine learning identifies prognostic subtypes of the tumor microenvironment of NSCLC

Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

CD8+ T cell-based cancer immunotherapy

HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Impact of NSCLC metabolic remodeling on immunotherapy effectiveness

PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

Adoptive immunotherapy via CD4+ versus CD8+ T cells

Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients

Machine learning identifies prognostic subtypes of the tumor microenvironment of NSCLC

Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

CD8+ T cell-based cancer immunotherapy

HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Impact of NSCLC metabolic remodeling on immunotherapy effectiveness

PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

Adoptive immunotherapy via CD4+ versus CD8+ T cells

Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients

Machine learning identifies prognostic subtypes of the tumor microenvironment of NSCLC

Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

CD8+ T cell-based cancer immunotherapy

HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Impact of NSCLC metabolic remodeling on immunotherapy effectiveness

PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

Adoptive immunotherapy via CD4+ versus CD8+ T cells

Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients

Machine learning identifies prognostic subtypes of the tumor microenvironment of NSCLC

Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy

Related objects

Reset password